|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0165 USD | +1.85% |
|
+13.79% | -96.00% |
| 04-10 | Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index | CI |
| 04-05 | Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index | CI |
April 17 (Reuters) - The U.S. Food and Drug Administration has approved Gamida Cell Ltd's blood cancer therapy, Omisirge, the health regulator said on Monday. (Reporting by Pratik Jain in Bengaluru)
| 1st Jan change | Capi. | |
|---|---|---|
| -96.00% | 2.5M | |
| +11.09% | 115B | |
| +12.73% | 106B | |
| -4.03% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -11.64% | 17.56B | |
| -39.36% | 17.32B | |
| +7.29% | 14.03B | |
| +32.94% | 12.13B |
GAMIDA CELL LTD. 
